Compare Neurocrine Biosciences Inc (NBIX) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while iShares 1 3 Year Treasury Bond ETF trades at $81.2 (market cap $26.68B). The key difference: iShares 1 3 Year Treasury Bond ETF is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| NBIX | SHY | |
|---|---|---|
Market Cap | $14.36B | $26.68B |
Volume | 1,237,180 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $185.50 | $83.18 |
52-Week Low | $123.10 | $81.05 |
Typical Hold Time | 23 Days | 63 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
SHY, a US stock, trades at $81.20 with minimal daily movement (+0.05%). The technical outlook is bearish, with moving averages signaling downward pressure and key indicators like the ADX_12 at 50.39 suggesting a strong trend. Recent corporate actions include scheduled dividends through late 2026, though financial ratios (P/E, P/S, etc.) are unavailable in the current snapshot. Market sentiment is influenced by broader bond market volatility, with news highlighting rising Treasury yields and geopolitical tensions impacting inflation expectations.
The outlook for SHY is cautious amid a bearish technical setup and macroeconomic headwinds, including higher interest rates and inflation concerns. Opportunities may arise from its dividend payments, but risks include sustained bond market sell-offs and economic uncertainty. Investors should weigh the stock's stability against potential volatility from external factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
